KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Receivables: 2018-2024

Historic Receivables for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $51.2 million.

  • Castle Biosciences' Receivables fell 1.55% to $49.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.4 million, marking a year-over-year increase of 18.12%. This contributed to the annual value of $51.2 million for FY2024, which is 33.72% up from last year.
  • Latest data reveals that Castle Biosciences reported Receivables of $51.2 million as of FY2024, which was up 33.72% from $38.3 million recorded in FY2023.
  • In the past 5 years, Castle Biosciences' Receivables ranged from a high of $51.2 million in FY2024 and a low of $12.8 million during FY2020.
  • Its 3-year average for Receivables is $37.7 million, with a median of $38.3 million in 2023.
  • As far as peak fluctuations go, Castle Biosciences' Receivables fell by 12.90% in 2020, and later skyrocketed by 63.15% in 2023.
  • Yearly analysis of 5 years shows Castle Biosciences' Receivables stood at $12.8 million in 2020, then surged by 35.45% to $17.3 million in 2021, then surged by 35.84% to $23.5 million in 2022, then soared by 63.15% to $38.3 million in 2023, then spiked by 33.72% to $51.2 million in 2024.